Journal
ONCOTARGETS AND THERAPY
Volume 8, Issue -, Pages 3361-3369Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S89275
Keywords
Bcl-2; non-small-cell lung cancer; meta-analysis; prognosis
Categories
Funding
- National Natural Science Foundation of China [81101761, 81172218]
- Shanghai science and technology commission foundation key project
- Longhua Medicial Project [D25]
- Ministry of Education Returned Scientific Research Foundation
- Shanghai Municipal Science and Technology Commission Foundation [14JC1401400]
- Trans-Century Training Programme Foundation for the Talents by the State Education Commission
- Shanghai Municipal Science and Technology Commission [15411951602]
Ask authors/readers for more resources
Objective: B-cell-lymphoma-2 (Bcl-2) is a proto-oncogene that plays an important role in the regulation of apoptosis and cell survival. However, there are much conflicting data in the literature concerning the association between Bcl-2 and prognosis in non-small-cell lung cancer (NSCLC). There is little in the way of meta-analysis focused on Bcl-2 and its effect on NSCLC prognosis. This study was performed to provide an assessment of whether expression levels of Bcl-2 are associated with prognosis in patients with NSCLC. Materials and methods: We searched PubMed, the Cochrane Library, and China National Knowledge Infrastructure for all eligible studies. The combined hazard ratios (HRs) and their corresponding 95% confidence intervals (CIs) in terms of overall survival were evaluated. Results: Fifty published studies including 6,863 patients with lung cancer were included in this meta-analysis. Overall, Bcl-2 was expressed in 33% of the NSCLC tumors studied. Our analysis indicates that NSCLC patients with Bcl-2-positive expression have a better prognosis than those with Bcl-2-negative expression in both Asian and non-Asian study populations (HR 0.79, 95% CI 0.72-0.87, P<0.00001). However, Bcl-2-positive expression seems to have no significant impact on survival of stage I NSCLC patients. Conclusion: Our results indicated that Bcl-2 might be a useful prognostic marker for NSCLC generally. Larger clinical trials are needed to confirm the prognostic value of Bcl-2 in stage I NSCLC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available